Early antiviral therapy of abidor combined with lopinavir/ritonavir and re-combinant interferonα-2b in patients with novel coronavirus pneumonia in Zhejiang: A multicenter and prospective study

Runan Wei; Nanhong Zheng; Xiangao Jiang; Chunlian MA; Xiaowei XU; Shourong Liu; Yongping Chen; Kaijin XU; Hainv Gao; Jiansheng Zhu; Qiang Shu; Jifang Sheng; Xiaoqiang Zhang; Minghui LI; Yan Zhang; Mengjie MA; Xuan Zhang; Shibo LI; Qiujing Wang; Lingjun Ying; Yongjun Zhang; Yunzhen Shi; Lingyan Fan; Wanjun YU; Huaying Wang; Dandan Sun; Xiaodong Wang; Jichan Shi; Yinghu Chen; Xinsheng Xie; Yunqing Chen; Weihong Wang; Zhaowei Tong; Lingling Tang; Mengfei Zhu; Lingjian Zhang; Lanjuan LI

Return

Early antiviral therapy of abidor combined with lopinavir/ritonavir and re-combinant interferonα-2b in patients with novel coronavirus pneumonia in Zhejiang: A multicenter and prospective study

VernacularTitle: 浙江省新型冠状病毒肺炎患者早期阿比多尔＋洛匹那韦/利托那韦＋重组干扰素α-2b联合抗病毒治疗的多中心、前瞻性研究
Author: Runan WEI ¹ ; Nanhong ZHENG ² ; Xiangao JIANG ³ ; Chunlian MA ⁴ ; Xiaowei XU ¹ ; Shourong LIU ⁵ ; Yongping CHEN ⁶ ; Kaijin XU ¹ ; Hainv GAO ⁷ ; Jiansheng ZHU ⁸ ; Qiang SHU ⁹ ; Jifang SHENG ¹ ; Xiaoqiang ZHANG ¹⁰ ; Minghui LI ¹¹ ; Yan ZHANG ¹ ; Mengjie MA ¹¹ ; Xuan ZHANG ¹ ; Shibo LI ¹ ; Qiujing WANG ¹² ; Lingjun YING ⁸ ; Yongjun ZHANG ¹³ ; Yunzhen SHI ¹³ ; Lingyan FAN ² ; Wanjun YU ¹⁴ ; Huaying WANG ¹⁴ ; Dandan SUN ¹⁰ ; Xiaodong WANG ⁶ ; Jichan SHI ³ ; Yinghu CHEN ⁹ ; Xinsheng XIE ¹⁵ ; Yunqing CHEN ¹⁵ ; Weihong WANG ¹⁶ ; Zhaowei TONG ¹⁶ ; Lingling TANG ⁷ ; Mengfei ZHU ⁷ ; Lingjian ZHANG ¹ ; Lanjuan LI ¹
Author Information

1. State key laboratory of diagnosis and treatment of infectious diseases, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou 310003, China
2. Department of Infectious Diseases, Ningbo Hwa Mei Hospital Affiliated to The University of Chinese Academy of Sciences, Ningbo 315010, China
3. Department of Infectious Diseases, Wenzhou Central Hospital, Wenzhou 325000, China
4. Department of Infectious Diseases, Wenling First people's Hospital, Taizhou 317500, China
5. Department of Infectious Diseases, Hangzhou Xixi Hospital, Hangzhou 310023, China
6. Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
7. Department of Infectious Diseases, Shulan (hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou 310004, China
8. Department of Infectious Diseases, Taizhou Enze Medical Center (Group) Enze hospital, Taizhou 317000, China
9. Department of Infectious Diseases, Children's hospital affiliated to Medical School of Zhejiang University, Hangzhou 310052, China
10. Department of Infectious Diseases, The First people's Hospital of Yuhang District, Hangzhou 310006, China
11. Department of Infectious Diseases, Shaoxing people's Hospital, Shaoxing 312000, China
12. Department of Infectious Diseases, Zhoushan Hospital, Zhoushan 316004, China
13. Department of Infectious Diseases, Dongyang people's Hospital, Jinhua 322100, China
14. Department of Infectious Diseases, Ningbo Yinzhou people's Hospital, Ningbo 315040, China
15. Department of Infectious Diseases, Jiaxing First Hospital, 314000 Jiaxing, China
16. Department of Infectious Diseases, Huzhou Central Hospital, Huzhou 313003, China
Collective Name:Zhejiang Novel Coronavirus Pneumonia Prevention and Control System and Clinical Treatment System Establishment and Research Group
Publication Type:Journal Article
Keywords: COVID-19; Antiviral therapy; Abidor; Lopinavir/ritonavir; Interferonα -2b
From: Chinese Journal of Clinical Infectious Diseases 2020;13(0):E010-E010
CountryChina
Language:Chinese
Abstract: Objective:Comparing the benefit of Abidor, lopinavir/ritonavir and recombinant interferon α-2b triple combination antiviral therapy and lopinavir/ritonavir and interferon dual combination antiviral therapy to hospitalized novel coronavirus pneumonia 2019 in Zhejiang province.
Methods:A multi-center prospective study was carried out to compare the effect of triple combination antiviral therapy with dual combination antiviral therapy in 15 medical institutions of Zhejiang Province. All patients were treated with recombinant interferon α-2b (5 million U, 2 times/d) aerosol inhalation. 196 patients were treated with abidol (200 mg, 3 times/d) + lopinavir / ritonavir (2 tablets, 1 time/12 h) as the triple combination antiviral treatment group. 41 patients were treated with lopinavir / ritonavir (2 tablets, 1 time/12 h) as the dual combination antiviral treatment group. The patients who received triple combination antiviral therapy were divided into three groups: within 48 hours, 3-5 days and > 5 days after the symptom onset. To explore the therapeutic effects of triple combination antiviral drugs and dual combination antiviral drugs, as well as triple combination antiviral drugs with different antiviral initiate time. SPSS17.0 software was used to analyze the data.
Results:The time of virus nucleic acid turning negative was (12.2 ± 4.7) days in the triple combination antiviral drug group, which was shorter than that in the dual combination antiviral drug group [(15.0 ± 5.0) days] (t = 6.159, P < 0.01 ). The length of hospital stay [12 (9, 17) d] in the triple combination antiviral drug group was also shorter than that in the dual combination antiviral drug group [15 (10, 18) d] (H = 2.073, P < 0.05). Comparing the antiviral treatment which was started within 48 hours, 3-5 days and > 5 days after the symptom onset of triple combination antiviral drug group, the time from the symptom onset to the negative of viral shedding was 13 (10,16.8), 17 (13,22) and 21 (18-24) days respectively (Z = 32.983, P < 0.01), and the time from antiviral therapy to the negative of viral shedding was (11.8±3.9) , (13.5±5.1) and (11.2±4.3) d. The differences among the three groups were statistically significant (Z=32.983 and 6.722, P<0.01 or<0.05).
Conclusions:The triple combination antiviral therapy of Abidor, Lopinavir/Litonavir and recombinant interferon α-2b showed shorter viral shedding time and hospitalization time compared with the dual combination antiviral therapy. The earlier the time to initiate triple antiviral treatment, the shorter the time of virus shedding.